Trials / Recruiting
RecruitingNCT04708171
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 453 (estimated)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a craniotomy where the resection boundaries for motor or language functions will be identified by the "awake" mapping technique (awake craniotomy, AC); 2) a craniotomy where the resection boundaries for motor functions will be identified by "asleep" mapping techniques (MEPs, SSEPs, continuous dynamic mapping); 3) a craniotomy where the resection boundaries will not be identified by any mapping technique ("no mapping group"). All patients will receive follow-up according to standard practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Awake mapping under local anesthesia | During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas. |
| PROCEDURE | Asleep mapping under general anesthesia | During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas. |
| PROCEDURE | Resection under general anesthesia without mapping | During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2025-10-01
- Completion
- 2026-10-01
- First posted
- 2021-01-13
- Last updated
- 2022-05-06
Locations
8 sites across 5 countries: United States, Belgium, Germany, Netherlands, Switzerland
Source: ClinicalTrials.gov record NCT04708171. Inclusion in this directory is not an endorsement.